PCSK9 and atherosclerosis: Given the shared mechanism of action and approximately equal reductions in lipid fractions it is very likely that LDL-C and Lp(a) lowering with inclisiran will have similar effects on ASCVD risk as the PCSK9 inhibiting monoclonals.